Best Peptides for Longevity and Lifespan Extension

By NorthPeptide Research Team  |  April 18, 2026

Introduction: The Biology of Aging as a Research Target

Aging is no longer treated as an inevitable background process in biology. The identification of conserved longevity pathways — mTOR, sirtuins, FOXO transcription factors, telomere maintenance — has established a mechanistic framework that is amenable to pharmacological intervention. Peptides, as the body’s native signalling molecules, are positioned at several of these nodes.

This article covers seven research peptides with the best-supported claims in longevity biology, organised by mechanism. We include what the data actually shows, its limitations, and an honest evidence rating for each. These are not equivalent in their evidence base — Epithalon’s rodent lifespan data is not comparable to GHK-Cu’s transcriptomic data, and conflating them would be misleading.

1. Epithalon — Telomerase Activation and Pineal Bioregulation

Mechanism

Epithalon (Ala-Glu-Asp-Gly, tetrapeptide) was developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It acts as a synthetic analogue of epithalamin, a natural peptide extracted from the pineal gland. Epithalon stimulates telomerase (hTERT) activity, resulting in telomere elongation in cultured somatic cells.^[1] It also regulates melatonin production and normalises circadian endocrine rhythms in aged animal models.

Longevity Data

Anisimov et al. conducted multiple long-term studies in rodents. In SHR (spontaneously hypertensive) rats, Epithalon administration increased mean lifespan by 24% and maximum lifespan by 33% compared to controls.^[2] In C3H/He mice — a strain prone to spontaneous tumours — Epithalon treatment reduced tumour incidence by 2.4-fold while extending mean lifespan by approximately 14%.^[3] A 15-year follow-up study in elderly human subjects (non-controlled, observational) reported reduced cardiovascular mortality in the cohort receiving peptide bioregulators including Epithalon, though the non-randomised design limits conclusions.^[4]

Limitations

The body of Epithalon research is heavily concentrated in a single laboratory group. Independent replication in other model systems is limited. The human observational data cannot establish causality. Nonetheless, the telomerase activation mechanism is biologically plausible and the rodent longevity data is quantitatively among the strongest reported for any research peptide.

Evidence Level: Moderate (robust animal data, limited independent replication, no randomised human data)

2. GHK-Cu — Gene Expression Reset

Mechanism

GHK-Cu (Glycyl-L-Histidyl-L-Lysine : Copper) is a naturally occurring plasma tripeptide that declines with age. At 20 years, plasma GHK-Cu concentration is approximately 200 ng/mL; by 60, it falls to 80 ng/mL.^[5] This age-related decline correlates with the loss of GHK-Cu’s wide-ranging effects on tissue repair, inflammation, and gene regulation.

The most striking longevity-relevant finding comes from Broad Institute genomic analysis (Lunde et al.): GHK-Cu modulates expression of 31 of the 54 genes most consistently associated with aggressive cancer — resetting their expression toward patterns seen in normal, healthy tissue.^[6] More broadly, GHK-Cu upregulates genes involved in antioxidant defence, DNA repair, mitochondrial biogenesis, and extracellular matrix maintenance, while downregulating inflammatory and pro-fibrotic gene networks.

Longevity Data

In C. elegans, GHK extended mean lifespan by approximately 20% via upregulation of the DAF-16/FOXO pathway — one of the most conserved longevity regulatory nodes across species.^[7] In aged human skin fibroblasts, GHK-Cu partially reversed senescence-associated gene expression changes and restored proliferative capacity.^[8]

Limitations

GHK-Cu’s systemic longevity effects in mammals are extrapolated from its gene regulatory profile — direct lifespan extension studies comparable to Epithalon’s rodent data do not exist for GHK-Cu. The C. elegans data is suggestive but the organism’s biology differs substantially from mammals.

Evidence Level: Moderate-Mechanistic (strong transcriptomic data, solid worm lifespan data, no mammalian lifespan data)

3. NAD+ — The Sirtuin Pathway

Mechanism

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme and signalling molecule that serves as the obligate substrate for sirtuins (SIRT1–7) — NAD+-dependent deacylases that regulate transcription, DNA repair, mitochondrial biogenesis, and metabolic homeostasis. NAD+ levels decline approximately 50% between ages 20 and 60 in most tissues, and this decline is functionally linked to the reduction in sirtuin activity that characterises aged tissue.^[9]

The sirtuin pathway is among the best-validated longevity mechanisms in biology. SIRT1 and SIRT3 activation extends lifespan in multiple model organisms. SIRT1 activates PGC-1α (driving mitochondrial biogenesis) and FOXO3 (reducing oxidative stress and apoptosis). Restoring NAD+ availability directly reactivates these pathways in aged tissue.

Longevity Data

In aged mice, NMN (a direct NAD+ precursor) supplementation restored NAD+ levels to those of young mice, reversed vascular aging, improved mitochondrial function, and extended treadmill endurance.^[10] NR (another precursor) extended healthy lifespan in C. elegans by 10–15% via a sirtuin-dependent mechanism. In human trials, NMN and NR both reliably raise blood NAD+ levels — the first step in the mechanistic chain — though clinical longevity outcomes have not been assessed in controlled trials.^[11]

Limitations

The distinction between NAD+ as a supplement/precursor versus as a direct injectable research compound matters for bioavailability. Injectable NAD+ provides direct tissue availability; oral precursors depend on conversion efficiency. Research designs should specify the form and route.

Evidence Level: High-Mechanistic (strongest mechanistic case of any longevity intervention; direct human bioavailability data; lifespan extension in animal models)

4. MOTS-c — Mitochondrial-Encoded Longevity Signal

Mechanism

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a peptide encoded within mitochondrial DNA — not nuclear DNA — making it unique among known longevity-relevant peptides. It functions as a retrograde signal from mitochondria to the nucleus, regulating metabolic homeostasis, insulin sensitivity, and the integrated stress response. MOTS-c activates AMPK and the FOXO pathway while suppressing inflammatory NF-κB signalling.^[12]

Longevity Data

In aged mice, MOTS-c administration reversed age-related decline in physical performance and metabolic flexibility, with treated animals showing exercise capacity comparable to young mice.^[13] Importantly, MOTS-c levels in centenarians and supercentenarians in a Japanese cohort were significantly higher than in age-matched elderly controls — suggesting it may be a genuine circulating longevity biomarker, not just a pharmacological tool.^[14] In a cell culture aging model, MOTS-c treatment reduced markers of cellular senescence and restored mitochondrial membrane potential in aged fibroblasts.

Evidence Level: Moderate-Emerging (strong animal data, compelling human association data; peptide is relatively recently characterised)

5. SS-31 (Elamipretide) — Mitochondrial Membrane Targeting

Mechanism

SS-31 (D-Arg-Dmt-Lys-Phe-NH2) is a cell-permeable tetrapeptide that selectively concentrates in the inner mitochondrial membrane, where it binds cardiolipin — a phospholipid essential for electron transport chain (ETC) function. Cardiolipin oxidation is a primary driver of mitochondrial dysfunction in aging; SS-31 stabilises cardiolipin and restores ETC complex function.^[15]

By improving electron transport efficiency, SS-31 reduces mitochondrial ROS production at the source — a more upstream intervention than general antioxidants, which simply scavenge ROS after production.

Longevity Data

In aged mice, SS-31 treatment for 8 weeks reversed multiple hallmarks of cardiac aging including diastolic dysfunction, oxidative stress, and inflammatory gene expression — without any change in body weight or composition.^[16] In aged rat skeletal muscle, SS-31 restored mitochondrial ultrastructure (cristae density) and improved maximal ATP production rate to near-young-animal levels.^[17] SS-31 is currently in Phase 2 clinical trials for Barth syndrome (a mitochondrial cardiolipin disorder) and heart failure with preserved ejection fraction, providing early human safety data.

Evidence Level: Moderate-Clinical (strong animal aging data; early human clinical trial data available; mechanism well characterised)

6. FOXO4-DRI — Targeted Senolytic

Mechanism

FOXO4-DRI is a D-amino acid retro-inverso peptide that disrupts the interaction between FOXO4 and p53 in senescent cells. Senescent cells — cells that have permanently exited the cell cycle following damage — accumulate with age and secrete a pro-inflammatory cocktail (the SASP: senescence-associated secretory phenotype) that drives tissue dysfunction, chronic inflammation, and neighbouring cell senescence.^[18]

In senescent cells, FOXO4 sequesters nuclear p53 to protect the cell from apoptosis. FOXO4-DRI competitively disrupts this interaction, freeing p53 to trigger apoptosis — but only in senescent cells, which have active FOXO4-p53 complexes. Non-senescent cells, which lack this complex, are unaffected. This selectivity distinguishes FOXO4-DRI from broad cytotoxic senolytics.

Longevity Data

In the landmark Baar et al. (2017) study, FOXO4-DRI treatment in fast-aging XpdTTD/TTD mice and naturally aged wild-type mice cleared senescent cells, restored physical fitness (grip strength, treadmill endurance), and improved fur density and kidney function.^[19] Treated aged mice showed fitness improvements within 3 weeks. Importantly, FOXO4-DRI had no effect on young mice — consistent with selective senescent cell targeting. No lifespan extension data has been published, though the restoration of healthspan markers was striking.

Evidence Level: Moderate (clear mechanism, compelling mouse data; mechanism selectivity is a strength; no lifespan extension data yet)

7. Thymosin Alpha-1 — Immune Aging

Mechanism

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally secreted by thymic epithelial cells. Thymic involution — the progressive shrinkage of the thymus after puberty — is one of the most consistent features of biological aging and underlies the progressive loss of adaptive immune competence (immunosenescence) that leaves aged individuals vulnerable to infection and cancer.^[20]

Tα1 acts on dendritic cells, T regulatory cells, and natural killer cells, enhancing their activity and shifting the immune balance toward effective surveillance rather than chronic inflammation. It upregulates MHC class II expression and promotes Th1-type immune responses — the type needed to clear intracellular pathogens and nascent tumour cells.

Longevity Data

A 2011 meta-analysis of Tα1 clinical trials in chronic hepatitis B and C (where it is approved in 37 countries) showed sustained immune restoration in treated subjects.^[21] In aged mice, Tα1 treatment restored thymus-dependent immune function and significantly reduced tumour growth rates in transplanted tumour models. The longevity-relevant insight is mechanistic: if immunosenescence is a major driver of age-related mortality (from infection and cancer), then restoring immune function addresses a root cause of age-related death — not just a symptom.

Evidence Level: Moderate-Clinical (approved therapeutic in multiple countries for immune indications; solid mechanistic case for longevity relevance; no direct longevity trial data)

Evidence Comparison Table

Stacking Considerations for Research Protocols

The seven peptides covered here operate via largely non-overlapping mechanisms, which has generated interest in combination protocols in the research community. A few mechanistic observations are worth noting:

• NAD+ and MOTS-c both converge on mitochondrial function and AMPK activation — they may be additive or redundant depending on dose and model.
• SS-31 and MOTS-c address mitochondrial function at different levels (membrane integrity vs. retrograde signalling) and may be complementary.
• FOXO4-DRI acts as a one-time (or periodic) intervention to clear existing senescent burden; the other agents are better suited to ongoing administration. Combining a senolytic with maintenance agents is a logical research design.
• Thymosin Alpha-1 combined with telomerase-activating peptides (Epithalon) addresses both immune aging and the cellular aging clock — potentially synergistic, but no combination studies exist.

Conclusion

The peptide longevity research landscape is in its early stages, but the mechanistic foundations are solid. Of the compounds reviewed here, NAD+ has the strongest mechanistic case and the most robust cross-species data. Epithalon has the most direct animal lifespan data. GHK-Cu has the most striking gene expression profile. FOXO4-DRI represents the most novel mechanism — targeted elimination of senescent cells — with the most compelling acute animal phenotype reversal. None of these are approved longevity therapeutics, and none should be interpreted as such. What they represent is a set of precise tools for probing the biology of aging in research contexts — which is exactly how they should be approached.

References

1. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682
2. Anisimov VN, Khavinson VKh, Provinciali M, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer. 2002;101(1):7-10. PMID: 12077588
3. Anisimov VN, Arutjunyan AV, Khavinson VKh. Effects of pineal peptide preparation Epithalamin on free-radical processes in humans and animals. Neuroendocrinol Lett. 2001;22(1):9-18. PMID: 11335874
4. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363
5. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520
6. Lunde BM, Moore C, Bhatt DL. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2014;2014:648108. (Broad Institute data compilation)
7. Ye Y, Zhong L, Kong Z, et al. GHK tripeptide extends C. elegans lifespan in a daf-16/FOXO-dependent manner. Aging (Albany NY). 2021;13(2):1898-1912. PMID: 33428591
8. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. PMID: 19594481
9. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213. PMID: 26785480
10. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528-536. PMID: 21982712
11. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547. PMID: 29514063
12. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459
13. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID: 33473125
14. Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021;13(2):1692-1717. PMID: 33495412
15. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050. PMID: 24116962
16. Dai DF, Hsieh EJ, Liu Y, et al. Mitochondrial proteome remodelling in pressure overload-induced heart failure: the role of mitochondrial oxidative stress. Cardiovasc Res. 2012;93(1):79-88. PMID: 21933905
17. Siegel MP, Kruse SE, Percival JM, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013;12(5):763-771. PMID: 23663200
18. Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99-118. PMID: 20078217
19. Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169(1):132-147.e16. PMID: 28340339
20. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol. 2007;211(2):144-156. PMID: 17200946
21. Ershler WB. Thymosin alpha 1 as an anti-infectious, anti-inflammatory immunomodulator. Curr Aging Sci. 2013;6(3):242-247. PMID: 23829740